Alto Neuroscience (ANRO) has moved back into focus after expanding its ALTO-207 program with an additional Phase 3 trial for treatment-resistant depression, supported by fresh funding and independent mechanism-of-action data.

The latest ALTO-207 update comes after a period of strong momentum for Alto Neuroscience, with a year-to-date share price return of 93.73% and a 1-year total shareholder return of about 9.2 times an initial investment. The recent 7-day and 30-day share price returns of 12.10% and 16.70% suggest investor interest has been building around the expanded trial program, fresh funding and recent earnings update.

If the ALTO-207 story has you looking more broadly at mental health and drug development, it is worth widening your search to other healthcare-focused AI opportunities via 42 healthcare AI stocks

After a move that has taken Alto Neuroscience to about $32.14, with analyst targets around $38.42 and no clear intrinsic value signpost yet, the real puzzle is where fair value sits within that spread.

Preferred Price-to-Book of 5.8x for Alto Neuroscience: Is it justified?

On a simple yardstick, Alto Neuroscience does not screen as cheap. The stock trades on a P/B of 5.8x, while the last close sits at $32.14 and peers in US Pharmaceuticals carry lower averages.

The P/B ratio compares the company’s market value to its book value, which is the net asset base on the balance sheet. For an early stage biopharmaceutical company with minimal current revenue and ongoing losses, a higher P/B often reflects how the market is weighing pipeline potential against present day financials.

Here, Alto Neuroscience has less than $1m in revenue and reported a loss of $84.24m, and it is forecast to remain unprofitable with no revenue expected next year. Against that backdrop, a 5.8x P/B suggests investors are placing a lot of weight on the clinical portfolio and future optionality rather than current earnings power.

The comparison with benchmarks is stark. Alto Neuroscience’s 5.8x P/B ratio is more than double the US Pharmaceuticals industry average of 2.5x and still sits above the peer average of 4x. That is a clear premium and points to expectations that are higher than both the wider group and more direct peers.

Result: Price-to-book of 5.8x (OVERVALUED)

However, Alto Neuroscience still faces meaningful risks, including ongoing losses of $84.24m and heavy reliance on successful outcomes from multiple early and mid stage trials.

Next Steps

With Alto Neuroscience priced at a premium and carrying clear risks, it may be useful to move quickly and review the available information for yourself. Start by reviewing the 3 important warning signs

Looking for more investment ideas beyond Alto Neuroscience?

If Alto Neuroscience has sharpened your interest, do not stop here. Use the tools available to keep building a broader, more resilient investing watchlist.

• Spot potential mispricing by checking companies that combine quality fundamentals with attractive valuations through the 52 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with robust yields and payout histories via the 10 dividend fortresses.
• Dial down portfolio risk by focusing on companies with steadier profiles using the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.